Skip to content

IDAP: Integrated Drug Annotation Pipeline

A modular evidence integration framework for precision oncology

IDAP combines four complementary evidence streams to prioritize therapeutic hypotheses for cancer patients based on somatic mutation data:

  • OncoKB -- Curated variant-drug associations with defined evidence levels
  • PubMed -- Literature-derived gene-drug mention evidence
  • TxGNN Knowledge Graph -- Graph-based drug prioritization using a biomedical knowledge graph
  • ClinicalTrials.gov -- Cancer-specific clinical trial metadata

Given a cancer type and a MAF file, IDAP generates patient-level reports summarizing detected variants, ranked therapeutic hypotheses, supporting evidence layers, and relevant clinical trials.

Key Features

  • Multi-source evidence integration across curated, literature, graph-based, and trial-linked data
  • Percentile-normalized scoring to prevent cross-source scale imbalance
  • Automated report generation with tabular and visual summaries (Excel + PDF)
  • Modular architecture allowing independent use or extension of each evidence module

Overview

IDAP Pipeline

Citation

If you use IDAP in your research, please cite:

Ryu Y, Jung H, An JY. IDAP: An integrated literature- and knowledge-graph-driven evidence prioritization pipeline for precision oncology. Bioinformatics (2026).